Adlai Nortye Ltd. (NASDAQ:ANL) Sees Significant Decrease in Short Interest

Adlai Nortye Ltd. (NASDAQ:ANL - Get Free Report) was the recipient of a large drop in short interest in the month of November. As of November 30th, there was short interest totalling 2,500 shares, a drop of 41.9% from the November 15th total of 4,300 shares. Based on an average daily volume of 15,200 shares, the short-interest ratio is presently 0.2 days.

Adlai Nortye Trading Up 2.8 %

ANL traded up $0.06 on Thursday, reaching $2.20. The company had a trading volume of 2,813 shares, compared to its average volume of 11,636. Adlai Nortye has a 52-week low of $1.85 and a 52-week high of $17.48. The business has a 50 day simple moving average of $2.29 and a 200 day simple moving average of $3.03.

Analyst Ratings Changes

Separately, HC Wainwright restated a "buy" rating and set a $9.00 target price on shares of Adlai Nortye in a research report on Monday, November 11th.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.